Rossari Biotech (ROSSARI) Q4 24/25 earnings summary

Executive summary

• FY 2025 saw steady growth and stable profitability, with revenue up 13.6% YoY, driven by a diversified business model, strong HPPC and export performance, and resilient volumes in key categories.

• Institutional cleaning and B2C businesses grew 67% YoY, reaching nearly INR 300 crores, and are now reported as a distinct vertical.

• R&D and innovation remained central, with the Reneva biosurfactant platform gaining traction and continued investments in capacity expansion and strategic acquisitions.

• Audited standalone and consolidated financial results for FY 2025 were approved with an unmodified opinion from statutory auditors.

• Final dividend of INR 0.5 per share recommended for FY 2025, subject to shareholder approval.

Financial highlights

• FY 2025 consolidated revenue reached INR 2,080.3 crores, up 13.6% YoY; EBITDA was INR 265.1 crores, up 6.1% YoY, with a margin of 12.7%.

• Q4 FY 2025 revenue was INR 579.6 crores, up 22.6% YoY; EBITDA at INR 69.5 crores, up 9.3% YoY.

• PAT for FY 2025 stood at INR 136.4 crores, up 4.4% YoY, with PAT margin at 6.6%.

• Basic EPS (consolidated) for FY 2025 was INR 24.66, up from INR 23.67 in FY 2024.

• Board recommended a dividend of INR 0.5 per share for FY 2025.

Outlook and guidance

• FY 2026 expected to see mid-teens revenue growth, with HPPC segment targeting low double-digit to mid-teens growth as EO supply improves.

• Margins for core business targeted at 14.5%-15% EBITDA; overall company margin expected at 13%-13.5%.

• Capacity expansion of 13,000 MTPA approved, to be completed by Q4 FY 2025-26, with an investment of INR 95 crores.

• Additional capex of INR 192 crores announced for expansions, with projects expected to be commissioned by Q4 FY 2026.

• FY 2027 anticipated as a strong year with CapEx coming online and improved EO availability.